Compare Danaher Corporation (DHR) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Microsoft — how do they compare? Danaher Corporation trades at $199.47 (market cap $140.88B), while Microsoft trades at $386.15 (market cap $2.86T). The key difference: Microsoft is far larger — about 20.3× Danaher Corporation's market cap, and Microsoft pays the higher dividend (0.95%). Which is the better fit depends on your goals.
| DHR | MSFT | |
|---|---|---|
Market Cap | $140.88B | $2.86T |
Sector | Health | Technology |
52-Week High | $242.05 | $542.07 |
52-Week Low | $161.91 | $352.83 |
Enterprise Value | $153.66B | $2.84T |
Dividend Yield | 0.8% | 0.95% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Microsoft (MSFT) trades at $390.99, up 1.53% today, with a neutral technical signal and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust at $281.72B for 2025, supported by 68.31% gross margins and $136.16B in operating cash flow. Analyst consensus is overwhelmingly bullish with 80.49% buy ratings and a $552.81 price target, representing 41% upside potential from current levels.
Microsoft's AI leadership and cloud momentum position it for continued growth, though elevated capital expenditures and competitive pressures present near-term headwinds. The stock's current valuation at 23.29 P/E appears reasonable given the company's strong profitability and growth trajectory. Institutional ownership remains substantial, with recent news highlighting Azure's strength and Copilot adoption as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
